Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering AG/Berlex Leukine To Enter Phase III For Crohn's In Early 2004

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Berlex’ Leukine is expected to enter Phase III development for moderately to severely active Crohn’s disease in early 2004, but the primary endpoint to be used is still being negotiated with FDA, the Schering AG subsidiary said Oct. 14.

You may also be interested in...



Schering AG To Continue Leukine Development In Wake Of Phase III Crohn’s Failure

Schering AG will continue clinical development of Leukine for Crohn's disease despite disappointing results from a Phase III induction trial

Elan Antegren Strategy: Separate Crohn’s Maintenance And Induction Claims

Elan/Biogen Idec’s regulatory strategy for gaining approval of Antegren (natalizumab) for Crohn’s disease appears to be centered on separating indications for induction and maintenance therapy.

Elan Antegren Strategy: Separate Crohn’s Maintenance And Induction Claims

Elan/Biogen Idec’s regulatory strategy for gaining approval of Antegren (natalizumab) for Crohn’s disease appears to be centered on separating indications for induction and maintenance therapy.

Related Content

Topics

UsernamePublicRestriction

Register

PS002416

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel